Robert W. Baird initiates coverage on Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) with an Outperform rating and $40 price target, citing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE